Amylyx Pharmaceuticals Inc Cash Flow Conversion Efficiency
Amylyx Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.42 Million) by net assets ($239.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Amylyx Pharmaceuticals Inc (2019–2025)
Cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Amylyx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AMLX live share price for real-time trading data and today's change.
Amylyx Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Amylyx Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Amylyx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Amylyx Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genworth Financial Inc
NYSE:GNW
|
0.005x |
|
FPT Corp
VN:FPT
|
-0.071x |
|
WNS Holdings Ltd
NYSE:WNS
|
0.037x |
|
Aris Mining Corporation
TO:ARIS
|
0.033x |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
0.001x |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
0.006x |
|
China Hainan Rubber Industry Group Co Ltd
SHG:601118
|
-0.035x |
|
Old Mutual Ltd
JSE:OMU
|
0.175x |
Annual Cash Flow Conversion Efficiency for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025. Review AMLX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.26 Million | $-123.34 Million | -0.404x | +60.29% |
| 2024-12-31 | $164.76 Million | $-167.65 Million | -1.017x | -3800.09% |
| 2023-12-31 | $433.43 Million | $11.92 Million | 0.027x | +105.21% |
| 2022-12-31 | $340.61 Million | $-179.87 Million | -0.528x | -206.73% |
| 2021-12-31 | $-151.17 Million | $-74.80 Million | 0.495x | -10.03% |
| 2020-12-31 | $-66.72 Million | $-36.70 Million | 0.550x | +30.49% |
| 2019-12-31 | $-25.36 Million | $-10.69 Million | 0.421x | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more